Free cash flow reached a positive $107.0M in 2026Q1, marking a significant turnaround from the $257.8M burn observed in 2023Q4.
| Cash from Operations | 57.25M | -66.93M | 34.84M | -115.87M | -203.93M | -282.33M | -118.5M | -159.88M | -153.28M |
| Operating CF Margin % | - | -3.48% | 2.54% | -9.19% | -18.6% | -19.18% | -17.61% | -34.59% | -54.54% |
| Operating CF Growth % | 619.11% | -292.09% | 130.07% | 43.18% | 27.77% | -138.25% | 25.88% | -4.3% | - |
| Net Income | -56.94M | -85.55M | -43.01M | -213.36M | -339.57M | -587.76M | -136.39M | -363.74M | -201.93M |
| Depreciation & Amortization | 1.22M | 1.69M | 1.33M | 2.51M | 1.19M | 1.25M | 0 | 551K | 487K |
| Stock-Based Compensation | 77.22M | 103.66M | 114.33M | 140.93M | 164.31M | 163.72M | 0 | 3.3M | 3.68M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -66.09M | 0 | 0 | 0 |
| Other Non-Cash Items | 18.51M | -2.53M | -50.66M | 9.48M | -27.49M | 13.88M | 42.35M | 167.7M | 9.51M |
| Working Capital Changes | 17.24M | -84.2M | 12.86M | -55.43M | -2.36M | 192.67M | -24.46M | 32.31M | 34.97M |
| Change in Receivables | -3.81M | 0 | -6.55M | 0 | -8.03M | -9.39M | 0 | 60.76M | -11.49M |
| Change in Inventory | 0 | - | - | - | - | - | - | - | - |
| Change in Payables | 5.66M | 0 | -2.62M | 4.74M | 7.63M | 5.31M | 0 | 6.3M | 0 |
| Cash from Investing | -9.92M | 4.08M | 565K | 140.01M | 95.13M | -435.45M | 141.31M | -181.91M | 97.53M |
| Capital Expenditures | -2.71M | -2.04M | -1.56M | -584K | -4.47M | -723K | -693K | -23K | -1.48M |
| CapEx % of Revenue | 0.12% | 0.11% | 0.11% | 0.05% | 0.41% | 0.05% | 0.1% | 0.01% | 0.53% |
| Acquisitions | 0 | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -434.72M | 0 | 0 | 99M |
| Cash from Financing | -29.51M | -53.38M | -17.36M | -33.86M | -4.96M | 925.39M | 1.94M | 333.98M | 74.59M |
| Debt Issued (Net) | 0 | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | -29.51M | -53.38M | -17.36M | -5.07M | -4.96M | 289.77M | 1.75M | 601K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -31.14M | -55.2M | -18.26M | -6.22M | -6.36M | -147K | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | -28.79M | 0 | 666.55M | -957K | -363K | 44.83M |
| Net Change in Cash | 17.83M | -116.24M | 18.05M | -9.72M | -113.75M | 207.62M | 92.35M | -7.8M | 18.83M |
| Free Cash Flow | 54.54M | -68.98M | 33.29M | -116.45M | -208.39M | -283.05M | -119.19M | -159.9M | -154.76M |
| FCF Margin % | 2.47% | -3.58% | 2.43% | -9.24% | -19% | -19.23% | -17.71% | -34.59% | -55.07% |
| FCF Growth % | 728.44% | -307.21% | 128.59% | 44.12% | 26.38% | -137.48% | 25.46% | -3.32% | - |
| FCF per Share | 0.10 | -0.13 | 0.07 | -0.24 | -0.44 | -0.60 | -0.29 | -0.40 | -3.68 |
| FCF Conversion (FCF/Net Income) | -0.96x | 0.78x | -0.81x | 0.54x | 0.60x | 0.48x | 0.87x | 0.44x | 0.76x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.26M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Regulatory reimbursement volatility
According to recent financial disclosures, Clover Health's operating cash flow reached $107.9M in 2026Q1, significantly outpacing net income of $27.3M, which suggests that the company's reported earnings are currently benefiting from substantial non-cash adjustments and favorable working capital movements rather than pure operational cash generation.
The wide variance between net income and operating cash flow warrants caution, as it indicates that accounting profits may not yet be fully supported by cash inflows. Investors should monitor whether this conversion gap persists as the company matures, as reliance on working capital swings to bolster cash flow is rarely sustainable over the long term.
As reported in quarterly filings, Clover Health's free cash flow trajectory has shifted from a $257.8M burn in 2023Q4 to a positive $107.0M in 2026Q1, reflecting a fundamental pivot toward fiscal discipline and the successful shedding of lower-margin, cash-intensive business segments within the insurance portfolio.
This transition to positive free cash flow appears to be a direct result of management's strategic focus on core Medicare Advantage profitability. While the improvement is notable, the sustainability of this trend remains contingent on the company's ability to maintain medical care ratios without the support of non-insurance revenue streams.
Based on the provided cash flow statements, working capital changes have been a primary driver of quarterly cash fluctuations, most notably contributing a $68.1M inflow in 2026Q1 compared to a $211.8M outflow in 2023Q4, highlighting the company's sensitivity to timing differences in CMS premium settlements and claim payments.
The high volatility in working capital suggests that Clover's cash position is susceptible to the timing of government reimbursements and the settlement of medical claims. This dependency implies that short-term liquidity may appear stronger or weaker than the underlying operational performance would otherwise suggest.
As indicated by historical data, Clover Health consistently records stock-based compensation expenses exceeding $25M per quarter, which effectively obscures the true cash cost of operations and suggests that the company's path to profitability is partially subsidized by significant dilution of existing shareholders' equity interests.
While stock-based compensation is a non-cash expense, it represents a real economic cost that should be factored into any assessment of the company's long-term cash generation capabilities. The reliance on equity-based incentives may indicate that management is attempting to preserve cash while still attracting the talent necessary to scale the Clover Assistant platform.
Quick answers to the most common questions about buying CLOV stock.
Clover Health Investments, Corp. (CLOV) generated $-66.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Clover Health Investments, Corp. (CLOV) reported negative free cash flow of $69.0M in 2025, indicating capital requirements exceeded cash from operations.
Clover Health Investments, Corp. (CLOV) spent $2.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Clover Health Investments, Corp. (CLOV) spent $55.2M on share repurchases. This shows the company's commitment to returning capital to its equity investors.